Nobel Laureate Joins Quintiles Scientific Advisory Board

Aaron Ciechanover, Winner of Nobel Prize in Chemistry, Joins Translational Research and Development Scientific Advisory Board

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles today announced the addition of Aaron Ciechanover, M.D., D.Sc., recipient of the Nobel Prize in Chemistry in 2004, to its Translational Research and Development Scientific Advisory Board. Dr. Ciechanover currently serves as a Distinguished Research Professor in the Faculty of Medicine of the Technion Israel Institute of Technology.

Along with Avram Hershko and Irwin Rose, Dr. Ciechanover received the Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation, which has become an important area of research for anti-cancer therapies.

The advisory board’s members are highly respected researchers and clinicians in oncology noted for novel scientific publications and collaborations with leading scientific institutions. The board’s purpose is to enhance Quintiles’ leadership in oncology drug development, especially in biomarker discovery and targeted therapies that result in better patient outcomes.

“I have been impressed by Quintiles’ key opinion leaders and scientific direction in oncology clinical development,” Dr. Ciechanover said. “I am pleased to join its advisory board to help advance promising anti-cancer therapies from research through development and on to patients in need.”

“Dr. Ciechanover’s work continues to provide translational research insight into novel mechanisms of action,” said Sarah Bacus, Ph.D., Quintiles Senior Vice President and Chief Scientific Officer, Translational R&D – Oncology. “His expertise will provide Quintiles with great insight into the next generation of anti-cancer drugs targeting the ubiquitin pathway.

“We are extremely pleased that he has joined other distinguished experts on Quintiles’ Scientific Advisory Board, and we look forward to Dr. Ciechanover’s involvement in our efforts to bring more effective oncology drugs to patients in need.”

With the addition of Dr. Ciechanover, Quintiles’ Translational Research and Development Scientific Advisory Board has 11 members representing some of the world’s most distinguished medical institutions, including Harvard Medical School, Johns Hopkins, Sloan-Kettering, MD Anderson Cancer Center, and the Spanish National Cancer Research Center (CNIO Spain).

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bio-pharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6392180&lang=en



CONTACT:

Quintiles
Jay Johnson, Media Relations, 919-998-7968
[email protected]
Greg Connors, Investor Relations, 919-998-2000
[email protected]

KEYWORDS:   United States  Europe  Asia Pacific  North America  South America  North Carolina

INDUSTRY KEYWORDS:   Technology  Other Technology  Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo
Photo
 Photo
Aaron Ciechanover, M.D., D.Sc., recipient of the Nobel Prize in Chemistry (Photo: Business Wire)

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.